Eli Lil­ly pays strug­gling Sang­amo $18M up­front to tap gene ther­a­py cap­sid

Eli Lil­ly is li­cens­ing Sang­amo Ther­a­peu­tics’ AAV cap­sid for an undis­closed CNS dis­ease tar­get, and the $18 mil­lion up­front fee should give the be­lea­guered biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER